Core Viewpoint - The announcements detail significant shareholder activities, including a reduction in shareholding by a major shareholder and the initiation of a share buyback program by the company [3][7]. Group 1: Shareholder Equity Changes - Major shareholder Liu Jianhua reduced his holdings by 1,911,900 shares on October 20, 2025, bringing his total shares from 74,341,860 to 72,429,960, which is a decrease in ownership percentage from 46.65% to 45.45% [3]. - This equity change touches the 1% threshold and is part of a previously disclosed reduction plan, not triggering a mandatory tender offer [3][4]. - The reduction is characterized as a normal divestment and will not significantly impact the company's governance structure or ongoing operations [3][4]. Group 2: Share Buyback Program - The company approved a share buyback plan on October 15, 2025, with a total budget between RMB 50 million and RMB 100 million, and a maximum buyback price of RMB 82 per share [7]. - As of October 20, 2025, the company has repurchased 377,400 shares, representing 0.24% of the total share capital, with a total expenditure of RMB 19,150,565 [8]. - The buyback is intended for employee stock ownership plans or equity incentives and will be conducted within a 12-month period following the board's approval [7][8].
北京康辰药业股份有限公司关于持股5%以上股东权益变动触及1%刻度的提示性公告